Journal of the American Society of Hypertension
Volume 2, Issue 5 , Pages 355-365.e2, September 2008

Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazide diuretic reduces coronary mortality and sudden cardiac death

  • Patricia R. Hebert, PhD

      Affiliations

    • Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
  • ,
  • Christopher S. Coffey, PhD

      Affiliations

    • Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA
  • ,
  • Daniel W. Byrne, MS

      Affiliations

    • Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  • ,
  • Theresa A. Scott, MS

      Affiliations

    • Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  • ,
  • Robert H. Fagard, MD, PhD

      Affiliations

    • Hypertension and Cardiovascular Rehabilitation Unit, University of Leuven K. U. Leuven, Leuven, Belgium
  • ,
  • Jeffrey N. Rottman, MD

      Affiliations

    • Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    • Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  • ,
  • Katherine T. Murray, MD

      Affiliations

    • Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    • Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    • Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  • ,
  • John A. Oates, MD

      Affiliations

    • Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    • Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    • Corresponding Author InformationCorresponding author: John A. Oates, MD, Vanderbilt Medical Center, 536 RRB, Nashville, Tennessee 37232. Tel: 615-343-4847; fax: 615-322-5303

Received 22 February 2008; accepted 1 April 2008. published online 24 June 2008.

Abstract 

No reduction in either coronary mortality or sudden cardiac death (SCD) has been demonstrated in overviews of randomized trials of treatment of hypertension with diuretics. An overview was conducted of coronary mortality and SCD in randomized controlled antihypertensive trials in which an epithelial sodium channel (ENaC) inhibitor/hydrochlorothiazide (HCTZ) combination was used. Secondarily, an analogous overview in which thiazide diuretic was used alone was performed. Randomized trials that used an ENaC inhibitor/HCTZ combination (or, alternatively, thiazide diuretic alone) were identified from previous meta-analyses, searches of PubMed, search of the Cochrane Clinical Trials database, and review of publications that addressed the consequences of treating hypertension. Trials in which participants were randomized to either an ENaC inhibitor combined with a thiazide diuretic (or to a thiazide diuretic alone) or to control treatment for at least 1 year and in which coronary mortality was reported were included. Numbers of events in individual trials were abstracted independently by two authors. Significant reductions in both coronary mortality and SCD were observed in the overview of trials in which elderly patients received an ENaC inhibitor/HCTZ combination. The odds ratio (OR) for coronary mortality was 0.59 (95% confidence interval [CI], 0.44 to 0.78) and for SCD was 0.60 (95% CI, 0.38 to 0.94). In contrast, an overview of the trials using thiazide diuretics alone showed no significant reductions of either coronary mortality (OR, 0.94; 95% CI, 0.81 to 1.09) or SCD (OR, 1.27; 95% CI, 0.93 to 1.75). Use of an ENaC inhibitor combined with HCTZ for treatment of hypertension in the elderly results in favorable effects on coronary mortality and SCD.

Keywords: Potassium, ventricular tachyarrhythmia, inhibitor/hydrochlorothiazide, meta-analysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported, in part, by a grant from the National Institute of General Medical Sciences (GM 15431). Dr. Oates is the Thomas F. Frist, Sr. Professor of Medicine and is a consultant for Merck. Supplemental Material is available at www.ashjournal.com.

PII: S1933-1711(08)00046-6

doi:10.1016/j.jash.2008.04.001

Journal of the American Society of Hypertension
Volume 2, Issue 5 , Pages 355-365.e2, September 2008